Heart stroke-volume variability in a murine model for heart failure with reduced ejection fraction

Gemma Fernández-Mendoza*

Departamento de Física, Escuela Superior de Física y Matemáticas,

Instituto Politécnico Nacional, 07738 Ciudad de México, México

Hugo J. Alves-Figueiredo and Gerardo de J. García-Rivas

Tecnológico de Monterrey

Moisés Santillán[†]

Centro de Investigación y de Estudios Avanzados,

Unidad Monterrey, 66628 Apodaca NL, México

(Dated: January 20, 2023)

Abstract

Write an abstract

I. INTRODUCTION

There is evidence that increased sympathetic nervous system activity is linked to increased cardiovascular morbidity and mortality [1]. On the other hand, heart rate variability (HRV) analysis has been widely used as a noninvasive assessment tool for autonomic nervous system function [2], and results show that decreased and/or abnormal HRV is associated with conditions such as congestive heart failure, diabetic neuropathy, post-cardiac-transplant depression, fatigue severity in chronic fatigue syndrome, and susceptibility to sudden infant dead syndrome [3–6].

Aside from the sympathetic and vagal nervous systems, the Frank-Starling mechanism and the force-frequency relationship are two basic mechanisms that regulate the heart's contractile strength in vivo [7] , and changes in all of them have been reported in patients with chronic heart failure [7–11]. This raises the possibility that other variables, such as stroke volume, which are critical for heart function, may be altered in such pathology. This question is addressed in the present manuscript, using a murine model for heart failure with reduced ejection fraction.

II. MATERIALS AND METHODS

III. RESULTS

A. Experimental and heart variability analysis

We conducted the experiments on the control and experimental groups according to the procedures outlined in Section Materials and Methods. We were able to calculate the heart's left ventricle volume as a function of time using the recorded data. This, along with the data on the ventricle pressure that was also recorded, made it possible to reconstruct for

---

* gemmag.fernandez@gmail.com

† http://moises-santillan.github.io; msantillan@cinvestav.mx

each experimental record the so-called P-V diagrams illustrated in Fig. 1. Thereafter, we were able to extract time series of physiological interest from these diagrams, such as those of successive cardiac-cycle periods and stroke volumes.


FIG. 1.

We took the time series of consecutive cardiac-cycle periods and calculated the mean cycle duration for each experimental record, then averaged all of the values obtained in each group. Figure 2A depicts the obtained results. No significative difference can be appreciated between the results of the control group and those of the group of mice with induced cardiac failure. This finding contradicts those of Kamen and Tonkin [3], who found increased heart rates in patients with chronic heart failure. However, keep in mind that the sympathetic and parasympathetic nervous systems control heart rate. In light of this, the fact that mice were anesthetized during the course of our experiments (with the resulting affection of the autonomic nervous system) may help to explain the outcomes.

We also calculated the mean values for the time series of consecutive stroke volumes for every experimental record. Then we averaged the results from each group and plotted the results in Fig. 2B. As expected, there is a significant reduction in stroke volume in the group with induced heart failure when compared to the control group.

We were interested in studying the variability of heart-cycle periods and stroke volumes. In this regard, a variety of techniques have been used to measure heart rate variability. The vast majority of them are founded on the concept of signal stationarity. However, the heart rate's inherent non-stationary nature—which undergoes continuous physiological change to adapt to external stimuli—presents a significant challenge that could result in inaccurate

3

FIG. 2. A) Average cardiac-cycle periods for control and experimental groups. B) Average stroke volumes for control and experimental groups.

results [12]. Although several signal preprocessing methodologies have been proposed to address these issues, nonlinear analysis-based strategies are commonly employed and appear to produce reliable results. [4, 12–17]. One of them that is used in different scientific domains is the Poincairé plot [16, 18, 19]. In a Poincairé plot, all values in a time series are plotted against previous values, resulting in an ellipsoidal point cloud. The standard deviations of the point projections along the lines $y = x$ (SD2) and $y = -x$ (SD1) can be used to quantitatively analyze this diagram. The transverse axis of the ellipse (SD1) is a measure of the short-term changes in the time series, while the longitudinal axis (SD2) reflects long-term changes. In the particular case of heart-beat duration time-series, SD1 is considered as an indicator of the parasympathetic activity, whereas SD2 is considered as an inverse indicator of the sympathetic activity [20].

We measured the above described Poincaré-plot indices of heart-cycle period variability for every experimental record, and averaged the results corresponding to the control and experimental groups. The outcomes are plotted in Fig. 3A. Observe that no statistically significative difference exists between the indices corresponding to the control and experimental groups. This suggests that, under our experimental conditions, heart failure does not affect heart rate variability (HRV). This finding contradicts Kamen and Tonkin [3] and other authors, who have reported that HRV decreases in patients with hart failure and we believe that it is also related to the fact that mice are anesthetized in our experimental

4

protocol.

FIG. 3.

The same methodology was used to investigate the variability of stroke volumes. The results are shown in Fig. 3B. The experimental group's SD1 and SD2 values are significantly lower than those of the control group. This suggests that heart failure affects the mechanisms in charge of controlling stroke volume. Furthermore, the absence of changes in HRV suggests that both types of variability are dissociated.

In summary, we found that, in our experimental protocol, there is no difference in the heart rate of mice with induced heart failure compared to those in the control group. The same is true for heart rate variability. These findings contradict previous reports, but we believe this discrepancy can be explained by the fact that the mice in our experiments are sedated. On the other hand, we found that, as expected, stroke volume decreases in mice with heart failure, as does stroke volume variability.

Reduced HRV has not only been observed in heart failure patients, but it has also been shown to be a strong predictor of cardiovascular events and mortality. Furthermore, HRV has been linked to a number of vascular risk factors, including hypertension, diabetes, depression, and subclinical inflammation [5]. We find it intriguing that the variability of stroke volume, which is also critical to heart function, is reduced in a pathology such as heart failure. What is more, our findings indicate that this decreased variability is caused by mechanisms other than those involved in HRV control. To gain some insight into this last question, we analyze in the following section a simple Frank-Starling model of the cardiovascular system that was previously introduced by Upton and Ludbrook [21].

FIG. 4. Schematic representation of the model

B. Mathematical Model

The model by Upton and Ludbrook is schematically represented in Fig. 4. It divides the blood in circulation into arterial and venous compartments. The pressure (P_x) and blood volume (V_x) in each compartment are related by the corresponding compliance (C_x):

$$P_x = V_x/C_x,$$

where subindex x can have the values A or V to represent the arterial and venous compartments. The flow of blood from the arterial compartment to the venous compartment is assumed to be passive. Hence, the blood volume exchanged during period Δt is:

$$V_R = \Delta t(P_A - P_V)/R,$$

in which R denotes the peripheral vascular resistance. Finally, to account for the Frank-Starling Law [22], the volume of blood transferred from the venous compartment to the arterial compartment by the heart pumping (stroke volume), is assumed to depend linearly on the venous pressure:

$$SV = \beta P_V.$$

This is the model's most daring assumption, as it integrates the pulmonary circulation of blood and its passage through the heart auricles and ventricles in a single step.

We now employ the Upton and Ludbrook model to investigate how the system's current state influences its evolution over successive cycles. To that end, we assume that the heart stroke occurs first, followed by passive diffusion of blood from the arterial compartment to the venous compartment. Let $V_{V,i}$ and $P_{V,i}$ denote the venous volume and pressure at the end of the i-th heart cycle. From this, the stroke volume in the next cycle is

$$SV_{i+1} = \beta P_{V,i}.$$

With this, the venous and arterial volumes after the heart stroke are:

$$V_{V,i+1/2} = V_{V,i} - SV_{i+1} \quad \text{and} \quad V_{A,i+1/2} = V_{A,i} + SV_{i+1}.$$

After some algebra, these expressions can be rewritten as

$$V_{V,i+1/2} = V_{V,i}\left(1 - \frac{\beta}{C_V}\right) \quad \text{and} \quad V_{A,i+1/2} = V_T - V_{V,i}\left(1 - \frac{\beta}{C_V}\right),$$

where V_T is the total blood volume, which is assumed constant because the system is closed. After the heart stroke, a volume $V_{R,i+1}$ of blood passively diffuses back to the venous compartment. This volume is given by

$$V_{R,i+1} = \frac{1}{R}\left[\frac{V_T}{C_A} - V_{V,i}\left(1 - \frac{\beta}{C_V}\right)\left(\frac{1}{C_A} + \frac{1}{C_V}\right)\right].$$

The venous and arterial volumes at the end of the $i+1$-th heart cycle can then be computed as:

$$V_{V,i+1} = V_{V,i} + V_{R,i+1} \quad \text{and} \quad V_{A,i+1} = V_{A,i} - V_{R,i+1}.$$

After performing the corresponding algebra, this last result leads to

$$V_{V,i+1} = V_{V,i}\left(1 - \frac{\beta}{C_V}\right)\left[1 - \frac{1}{R}\left(\frac{1}{C_A} + \frac{1}{C_V}\right)\right] + \frac{V_T}{RC_A}.$$

Finally, taking into account that $SV_{i+1} = \beta V_{V,i}/C_V$, it follows that

$$SV_{i+1} = \mathcal{A}\,SV_i + \mathcal{B},$$

with

$$\mathcal{A} = \left(1 - \frac{\beta}{C_V}\right)\left[1 - \frac{1}{R}\left(\frac{1}{C_A} + \frac{1}{C_V}\right)\right],$$

$$\mathcal{B} = \frac{V_T\beta}{RC_AC_V}.$$

In other words, we derived a recursive expression for the stroke volume in consecutive heart cycles from the Upton and Ludbrook [21] model. It can be straightforwardly proved that such recursive equation converges to the stationary value

$$\overline{SV} = \frac{\mathcal{B}}{1 - \mathcal{A}},$$

whenever $|\mathcal{A}| < 1$. Furthermore, the closer $\mathcal{A}$ is to 0, the faster the recursive equation converges to its stationary value.

The previous results imply that, when additive noise is included in the model, stroke volume variability is reduced for smaller $\mathcal{A}$ values. Take note, in particular, that $\mathcal{A}$ is a decreasing function of β. The decrease in short-term stroke volume variability observed in our experiments could then be explained by an increase in parameter β, which is related to the Frank-Starling mechanism. Interestingly, Holubarsch *et al.* [7] discovered, despite previous controversy, that the Frank-Starling mechanism is maintained in end-stage failing human hearts. They also found evidence that diastolic compliance was reduced in isolated preparations of failing human ventricles, indicating that higher end-diastolic stresses and pressures are required in failing hearts compared to normal hearts to achieve optimal contractile force. This might be translated into changes of parameter β in our model and possibly explain the observed stroke volume variability.

IV. CONCLUDING REMARKS

The available epidemiological and clinical data link increased sympathetic nervous system activity to increased cardiovascular morbidity and mortality, demonstrating that it has a strong predictive power for mortality and cardiovascular events [1]. Heart rate variability (HRV) analysis has been widely used as a noninvasive assessment tool for autonomic nervous system function [2], and results show that decreased and/or abnormal HRV is associated with conditions such as congestive heart failure, diabetic neuropathy, post-cardiac-transplant depression, fatigue severity in chronic fatigue syndrome, and susceptibility to sudden infant dead syndrome have been associated with modified (usually lower) heart rate variability [3–6].

We found that stroke volume variability (SVV) decreases in a murine model for heart failure with reduced ejection fraction. Our results indicated that stroke volume variability is

independent HRV, and the analysis of a simple model of the cardiovascular system suggests that the observed SVV reduction may be related to the Frank-Starling mechanism.

The Frank-Starling mechanism, along with the force-frequency relationship and the sympathetic and vagal nervous systems, is one of the basic mechanisms that regulate the contractile strength of the heart in vivo [7]. Significant changes in the force-frequency relationship and the β-adrenoceptor system have been described in detail for failing human myocardium [8–11], with the latter resulting in reduced HRV. However, this cannot explain SVV reduction in our experiments. Through a carefully planned set of experiments at the cell, organ, and organism levels, Holubarsch *et al.* [7] demonstrated that the Frank-Starling mechanism is well preserved in failing human myocardium. They also discovered significant changes in diastolic myocardial distensibility in patients with chronic heart failure. We speculate that these changes are at the root of the observed SVV reduction.

[1] S. C. Malpas, Sympathetic nervous system overactivity and its role in the development of cardiovascular disease, Physiological Reviews **90**, 513 (2010).

[2] K. Kiyono, J. Hayano, E. Watanabe, and Y. Yamamoto, Heart rate variability (HRV) and sympathetic nerve activity, in *Clinical Assessment of the Autonomic Nervous System* (Springer Japan, 2016) pp. 147–161.

[3] P. W. Kamen and A. M. Tonkin, Application of the poincaré plot to heart rate variability: a new measure of functional status in heart failure, Australian and New Zealand Journal of Medicine **25**, 18 (1995).

[4] U. R. Acharya, K. P. Joseph, N. Kannathal, C. M. Lim, and J. S. Suri, Heart rate variability: a review, Medical & Biological Engineering & Computing **44**, 1031 (2006).

[5] A. Z. A. Hazzouri, M. N. Haan, Y. Deng, J. Neuhaus, and K. Yaffe, Reduced heart rate variability is associated with worse cognitive performance in elderly mexican americans, Hypertension **63**, 181 (2014).

[6] R. M. Escorihuela, L. Capdevila, J. R. Castro, M. C. Zaragozà, S. Maurel, J. Alegre, and J. Castro-Marrero, Reduced heart rate variability predicts fatigue severity in individuals with chronic fatigue syndrome/myalgic encephalomyelitis, Journal of Translational Medicine **18**, 10.1186/s12967-019-02184-z (2020).

[7] C. Holubarsch, T. Ruf, D. J. Goldstein, R. C. Ashton, W. Nickl, B. Pieske, K. Pioch, J. Lu¨demann, S. Wiesner, G. Hasenfuss, H. Posival, H. Just, and D. Burkhoff, Existence of the frankstarling mechanism in the failing human heart, Circulation **94**, 683 (1996).

[8] L. A. Mulieri, G. Hasenfuss, B. Leavitt, P. D. Allen, and N. R. Alpert, Altered myocardial force-frequency relation in human heart failure., Circulation **85**, 1743 (1992).

[9] B. Pieske, G. Hasenfuss, C. Holubarsch, R. Schwinger, M. Böhm, and H. Just, Alterations of the force-frequency relationship in the failing human heart depend on the underlying cardiac disease, in *Cellular and Molecular Alterations in the Failing Human Heart* (Steinkopff, 1992) pp. 213–221.

[10] M. R. Bristow, R. Ginsburg, W. Minobe, R. S. Cubicciotti, W. S. Sageman, K. Lurie, M. E. Billingham, D. C. Harrison, and E. B. Stinson, Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts, New England Journal of Medicine **307**, 205 (1982).

[11] M. R. Bristow, R. E. Hershberger, J. D. Port, W. Minobe, and R. Rasmussen, Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium., Molecular Pharmacology **35**, 295 (1989).

[12] N. Marwan, M. Carmenromano, M. Thiel, and J. Kurths, Recurrence plots for the analysis of complex systems, Physics Reports **438**, 237 (2007).

[13] N. Marwan, N. Wessel, U. Meyerfeldt, A. Schirdewan, and J. Kurths, Recurrence-plot-based measures of complexity and their application to heart-rate-variability data, Physical Review E **66**, 10.1103/physreve.66.026702 (2002).

[14] A. E. Aubert, B. Seps, and F. Beckers, Heart rate variability in athletes, Sports Medicine **33**, 889 (2003).

[15] A. Giuliani, G. Piccirillo, V. Marigliano, and A. Colosimo, A nonlinear explanation of aging-induced changes in heartbeat dynamics, American Journal of Physiology-Heart and Circulatory Physiology **275**, H1455 (1998).

[16] C. L. Webber and J. P. Zbilut, Dynamical assessment of physiological systems and states using

recurrence plot strategies, Journal of Applied Physiology **76**, 965 (1994).

[17] T. Henriques, M. Ribeiro, A. Teixeira, L. Castro, L. Antunes, and C. Costa-Santos, Nonlinear methods most applied to heart-rate time series: A review, Entropy **22**, 309 (2020).

[18] R. A. Hoshi, C. M. Pastre, L. C. M. Vanderlei, and M. F. Godoy, Assessment of heart rate complexity recovery from maximal exercise using recurrence quantification analysis, in *Springer Proceedings in Physics* (Springer International Publishing, 2016) pp. 157–168.

[19] A. Voss, S. Schulz, R. Schroeder, M. Baumert, and P. Caminal, Methods derived from non-linear dynamics for analysing heart rate variability, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences **367**, 277 (2008).

[20] G. Zimatore, M. C. Gallotta, M. Campanella, P. H. Skarzynski, G. Maulucci, C. Serantoni, M. D. Spirito, D. Curzi, L. Guidetti, C. Baldari, and S. Hatzopoulos, Detecting metabolic thresholds from nonlinear analysis of heart rate time series: A review, International Journal of Environmental Research and Public Health **19**, 12719 (2022).

[21] R. N. Upton and G. L. Ludbrook, Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs — method development and application to magnesium in sheep, BMC Pharmacology **5**, 5 (2005).

[22] R. Jacob, B. Dierberger, and G. Kissling, Functional significance of the frank-starling mechanism under physiological and pathophysiological conditions, European Heart Journal **13**, 7 (1992).